Valuation: Axsome Therapeutics, Inc.

Market Cap 11.84B 10.37B 9.59B 8.82B 16.67B 1,141B 16.92B 114B 44.89B 558B 44.44B 43.47B 1,923B P/E 2026 *
-110x
P/E 2027 * 41.3x
Enterprise Value 11.73B 10.27B 9.5B 8.73B 16.51B 1,131B 16.77B 113B 44.47B 553B 44.03B 43.06B 1,905B EV / Sales 2026 *
12x
EV / Sales 2027 * 7.19x
Free-Float
84.36%
Yield 2026 *
-
Yield 2027 * -
1 day-3.63%
1 week-5.20%
Current month-9.45%
1 month-11.52%
3 months+17.28%
6 months+25.03%
Current year+21.35%
1 week 221.21
Extreme 221.21
240.86
1 month 221.21
Extreme 221.21
253
Current year 152.28
Extreme 152.28
260.19
1 year 96.09
Extreme 96.09
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/11/26 Sell

Director

-286 0.0006%
6/10/26 Sell

Director

-300 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-3.63%-5.20%+98.42%+198.55% 11.84B
-0.67%+1.15%+23.89%-6.52% 68.85B
-0.54%+0.38%+36.12%+192.81% 52.13B
-3.65%+34.50%+34.50%+34.50% 43.46B
-0.58%-0.23%-52.36%-53.82% 41.24B
-2.93%+0.40%+59.97%-27.79% 30.41B
-3.77%-12.86%+90.31%-52.47% 24.53B
-1.36%-0.91%+70.42%+83.86% 23.42B
+3.99%+3.12%+3.87%+200.81% 19.75B
+0.26%-1.74%+70.47%+125.19% 16.57B
Average -0.92%-1.08%+43.56%+69.51% 33.22B
Weighted average by Cap. -1.03%-0.50%+33.01%+51.49%

Financials

2026 *2027 *
Net sales 978M 857M 792M 728M 1.38B 94.3B 1.4B 9.46B 3.71B 46.1B 3.67B 3.59B 159B 1.59B 1.4B 1.29B 1.19B 2.24B 154B 2.28B 15.4B 6.04B 75.06B 5.98B 5.85B 259B
Net income -108M -95.01M -87.86M -80.77M -153M -10.46B -155M -1.05B -411M -5.11B -407M -398M -17.62B 308M 270M 249M 229M 434M 29.69B 440M 2.98B 1.17B 14.52B 1.16B 1.13B 50.03B
Net Debt -111M -97M -89.7M -82.46M -156M -10.68B -158M -1.07B -420M -5.22B -416M -407M -17.99B -394M -345M -319M -293M -554M -37.98B -563M -3.81B -1.49B -18.57B -1.48B -1.45B -63.99B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,220
Date Price Change Volume
26-07-20 $221.64 -3.63% 776,044
26-07-17 $230.00 -2.97% 878,315
26-07-16 $237.04 -0.21% 639,658
26-07-15 $237.53 +0.96% 838,870
26-07-14 $235.26 +3.06% 482,756
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
230.00USD
Average target price
280.39USD
Spread / Average Target
+21.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock